Anmelden

Open Access

  • Startseite
  • Suchen
  • Browsen
  • Veröffentlichen
  • Hilfe

Filtern

Autor

  • Brangsch, J. (2)
  • Hamm, B. (2)
  • Kader, A. (2)
  • Kaufmann, Jan O. (2)
  • Makowski, M. R. (2)
  • Adams, L. C. (1)
  • Borde, T. (1)
  • Buchholz, R. (1)
  • Karst, U. (1)
  • Keller, S. (1)
+ weitere

Erscheinungsjahr

  • 2021 (1)
  • 2020 (1)

Schlagworte

  • Magnetic resonance imaging (2)
  • Diagnosis (1)
  • ESMA (1)
  • Elastin-specific molecular agent (1)
  • Extracellular matrix (1)
  • Gadolinium (1)
  • Hepatocellular carcinoma (1)
  • Imaging (1)
  • Inductively coupled plasma mass spectroscopy (1)
  • Laser ablation-inductively coupled plasma-mass spectrometry (1)
+ weitere

Organisationseinheit der BAM

  • 1 Analytische Chemie; Referenzmaterialien (2)
  • 1.5 Proteinanalytik (2)

2 Treffer

  • 1 bis 2
  • CSV
  • RIS
  • 10
  • 20
  • 50
  • 100

Sortieren nach

  • Jahr
  • Jahr
  • Titel
  • Titel
  • Autor
  • Autor
Molecular MR Imaging of Prostate Cancer (2021)
Kader, A. ; Brangsch, J. ; Kaufmann, Jan O. ; Zhao, J. ; Mangarova, D. B. ; Moeckel, J. ; Adams, L. C. ; Sack, I. ; Taupitz, M. ; Hamm, B. ; Makowski, M. R.
This review summarizes recent developments regarding molecular imaging markers for magnetic resonance imaging (MRI) of prostate cancer (PCa). Currently, the clinical standard includes MR imaging using unspecific gadolinium-based contrast agents. Specific molecular probes for the diagnosis of PCa could improve the molecular characterization of the tumor in a non-invasive examination. Furthermore, molecular probes could enable targeted therapies to suppress tumor growth or reduce the tumor size.
Assessment of the hepatic tumor extracellular matrix using elastin‑specific molecular magnetic resonance imaging in an experimental rabbit cancer model (2020)
Keller, S. ; Borde, T. ; Brangsch, J. ; Reimann, C. ; Kader, A. ; Schulze, D. ; Buchholz, R. ; Kaufmann, Jan O. ; Karst, U. ; Schellenberger, E. ; Hamm, B. ; Makowski, M. R.
To investigate the imaging performance of an elastin-specific molecular magnetic resonance imaging (MRI) probe with respect to the extracellular matrix (ECM) in an experimental hepatic cancer model. Twelve rabbits with hepatic VX2 tumors were examined using 3 T MRI 14, 21, and 28 days after tumor implantation for two subsequent days (gadobutrol, day 1; elastin-specific probe, day 2). The relative enhancement (RE) of segmented tumor regions (central and margin) and the peritumoral matrix was calculated using pre-contrast and delayed-phase T1w sequences. MRI measurements were correlated to histopathology and element-specific and spatially resolved mass spectrometry (MS). Mixed-model analysis was performed to assess the performance of the elastin-specific probe. In comparison to gadobutrol, the elastin probe showed significantly stronger RE, which was pronounced in the tumor margin (day 14–28: P ≤ 0.007). In addition, the elastin probe was superior in discriminating between tumor regions (χ2(4) = 65.87; P < 0.001). MRI-based measurements of the elastin probe significantly correlated with the ex vivo elastinstain (R = .84; P <0 .001) and absolute gadolinium concentrations (ICP-MS: R = .73, P <0 .01). LA-ICP-MS imaging confirmed the colocalization of the elastin-specific probe with elastic fibers. Elastin-specific molecular MRI is superior to non-specific gadolinium-based contrast agents in imaging the ECM of hepatic tumors and the peritumoral tissue.
  • 1 bis 2

OPUS4 Logo

  • Kontakt
  • Impressum
  • Sitelinks